Swiss neurotech company Indivi acquired Cogitat, an Imperial College London spin-out. Cogitat develops deep learning models that decode cognitive function from EEG brain signals. The deal brings Cogitat's NeuroRVQ foundation model into Indivi's platform.
Alzheimer's focus
Indivi expects NeuroRVQ to change how drug developers measure whether brain disease treatments are working. EEG offers a more direct window into brain activity than existing methods. It may detect changes before memory and thinking problems become clinically visible.
Indivi's platform
Indivi is headquartered in Basel, Switzerland, with offices in Córdoba, Spain, and Boston, Massachusetts. Its multimodal platform includes smartphone-based motor and cognitive assessments. The company works in Parkinson's disease, FSHD, multiple sclerosis, and Alzheimer's disease and related dementias.
How NeuroRVQ works
NeuroRVQ learns patterns of brain activity and preserves fine, fast-changing detail. Its brainwave decoders are designed to work across different brains without individual training. Indivi aims to use this detail to pick up subtler signs of disease and treatment response.
NeuroRVQ will be presented at NeurIPS 2026 from December 6 to 12. The company expects to apply the model to treatment efficacy in Alzheimer's and related dementias. Over time, the model could also power new healthcare and consumer applications.